Sanofi SA

Type: Company
Name: Sanofi SA
Nationality: France
Web Address: http://en.sanofi.com/
First reported 1 hour ago - Updated 1 hour ago - 1 reports

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

Effective antiplatelet therapy combining the inhibition of both thromboxane A 2 –dependent platelet aggregation and P2Y 12 receptors is necessary in patients undergoing percutaneous coronary intervention (PCI), particularly those with ST-segment elevation ... [Published New England Journal of Medicine - 1 hour ago]
First reported Aug 31 2014 - Updated 3 hours ago - 12 reports

Cholesterol Drug Halves Heart Attack and Stroke in Early Test

BARCELONA — An experimental cholesterol[1]-lowering drug from Sanofi[2] and Regeneron Pharmaceuticals[3] cut roughly in half the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.The result is not conclusive, because ... [Published DailyMe.Com - 3 hours ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Sarah Ketterer's Causeway International Value Fund Reports Top Five

Sarah Ketterer is the CEO and co-founder of Causeway. She is the portfolio manager for the firm’s fundamental and absolute returns strategies, and is responsible for investment research across all sectors. Ketterer along with Conor Muldoon, Jonathan Eng, ... [Published Guru Focus - 6 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Sanofi Appoints New President, North America Pharmaceuticals

Sanofi has appointed Jez Moulding to the position of president, North America Pharmaceuticals. Moulding will lead the Sanofi North America Pharmaceuticals business with a portfolio that includes: diabetes, cardiovascular, renal, biosurgery, specialty ... [Published PharmaAsia - 16 hours ago]
First reported 20 hours ago - Updated 18 hours ago - 2 reports

Alirocumab bests ezetimibe for LDL reduction in ODYSSEY studies

BARCELONA, Spain — New data from the ODYSSEY clinical trials program demonstrate significant LDL reductions with the investigational PCSK9 inhibitor alirocumab compared with ezetimibe and placebo.The ODYSSEY FH I and II trials were designed to evaluate ... [Published Orthopedics Today - 18 hours ago]
First reported Aug 31 2014 - Updated Aug 31 2014 - 1 reports

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial

Group Information: A list of the SOLID-TIMI 52 Investigators is included in Supplement 1 .Corresponding Author: Michelle L. O’Donoghue, MD, MPH, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 350 Longwood Ave, First Floor, Boston, ... [Published Journal of the American Medical Association - Aug 31 2014]
First reported Aug 31 2014 - Updated Aug 31 2014 - 1 reports

Sanofi-Regeneron's Amgen Drug Rival Cuts Cholesterol - Bloomberg

Sanofi-Regeneron's Amgen Drug Rival Cuts Cholesterol Bloomberg ... to be number one,” Elias Zerhouni, Sanofi's head of research and development, said in a telephone interview. Sales of alirocumab may reach 1 billion euros ($1.3 billion) by 2020, ... [Published Bloomberg via Google News - Aug 31 2014]
First reported Aug 31 2014 - Updated Aug 31 2014 - 1 reports

As battle over AstraZeneca looms, one lab in Slough shows mergers can work

The bid from Pfizer, now active again, has caused widespread anger. But another takeover 10 years ago was a different story How it could be for AstraZeneca: the UCB biotech lab in Slough, once home to British company Celltech until taken over – and ... [Published Guardian.co.uk - Aug 31 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 5 reports

Global Adhesion Barriers Market 2014-2018: Key Vendors are Baxter, Covidien, Ethicon and Sanofi

DUBLIN, August 29, 2014 /PRNewswire/ -- Dublin - Research and Markets (http://www.researchandmarkets.com/research/h73gdt/global_adhesion) has announced the addition of the "Global Adhesion Barriers Market 2014-2018" report to their... ... [Published PR Newswire: General Business - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 2 reports

Bloomberg: Sale of OTC specialist Omega could top $5.3B with bids from Bayer, Sanofi

Bayer CEO Marijn DekkersWhat's an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium's Omega Pharma.The up-for-sale company has so far drawn interest from suitors ... [Published FiercePharma - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 4 reports

Amgen And Sanofi Compete To Launch New Class Of Cholesterol-Fighting Drugs

Amgen has filed a Biologics License Application with the FDA for a new class of cholesterol-fighting drugs. It is competing with Sanofi to be the first to tap into the $10 billion marketPage 1 of 2Click Ticker to See live coverageAmgen, Inc. ( AMGN ) ... [Published Bidness Etc - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 3 reports

Pfizer Takes Lead Over Sanofi With Fast-Track Designation Of Its C. Difficile Vaccine

Pfizer has received the FDA’s fast-track designation for its new CDI-preventive vaccine, and the designation has helped the company surge past its rival, Sanofi, which had been in the lead until nowPage 1 of 2Click Ticker to See live coverageThe US Food ... [Published Bidness Etc - Aug 29 2014]

Quotes

"Our divestment in Globalpharma was well-timed as we capitalised on the rapid growth in the pharmaceutical sector in the region. With the direction and backing of DI, the management executed a successful strategy and created an opportunity for a lucrative divestment" Kalban added
"Jez brings 20 years of valuable experience to North America Pharmaceuticals that he gained within complex and dynamic markets, said Peter Guenter, executive vice president, Global Commercial Operations at Sanofi. "This experience will serve him well in the evolving US and Canadian healthcare environments.""
...of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "We are also encouraged by the consistent safety profile across the trials, including in ODYSSEY LONG TERM, the largest Phase III trial of a PCSK9 inhibitor, with the longest follow-up period reported to date" she added
"Given that the primary cardiovascular effect of ivabradine is to reduce heart rate, these results suggest that an elevated heart rate is only a marker of risk—but not a modifiable determinant of outcomes—in patients who have stable coronary artery disease without clinical heart failure" according to Prof Kim Fox (Imperial College, Royal Brompton Hospital, London UK) and colleagues

More Content

All (2313) | News (1735) | Reports (0) | Blogs (467) | Audio/Video (2) | Fact Sheets (32) | Press Releases (70)
sort by: Date | Relevance
Dubai Investment PJSC : DI profit up 118pc [Published 4 Traders - 33 mins ago]
Prehospital Ticagrelor in ST-Segment Elevation ... [Published New England Journal of Medicine - 1 hour ago]
U300 Insulin Glargine Produces Lower Rates of N... [Published Diabetes in Control - 2 hours ago]
Cholesterol Drug Halves Heart Attack and Stroke... [Published DailyMe.Com - 3 hours ago]
Sarah Ketterer's Causeway International Value F... [Published Guru Focus - 6 hours ago]
Pharma co shares in limelight with better Q1 pe... [Published PharmaBiz - 6 hours ago]
Cholesterol control drug breakthrough [Published Times Live South Africa - 11 hours ago]
Early Hint At Cardiovascular Outcomes With Sano... [Published Forbes.com - 16 hours ago]
Sanofi Appoints New President, North America Ph... [Published PharmaAsia - 16 hours ago]
Alirocumab bests ezetimibe for LDL reduction in... [Published Orthopedics Today - 18 hours ago]
Positive results from four pivotal alirocumab t... [Published Pharma Letter - 18 hours ago]
SIGNIFY: No Ivabradine Clinical Outcomes Gain i... [Published Diabetes Care - 19 hours ago]
Sanofi, Regeneron's PCSK9 inhibitor alirocumab ... [Published FirstWord Pharma - 19 hours ago]
Huge Decreases in LDL Cholesterol With Alirocum... [Published American Journal of Public Health - 20 hours ago]
Sanofi, Regeneron point to potential heart bene... [Published FierceBiotech - 21 hours ago]
Early data suggest Sanofi, Regeneron drug may h... [Published DailyMe.Com - 21 hours ago]
Effect of Darapladib on Major Coronary Events A... [Published Journal of the American Medical Association - Aug 31 2014]
Sanofi, Regeneron Report Positive Results From ... [Published RTTNews.com - Aug 31 2014]
Sanofi-Regeneron's Amgen Drug Rival Cuts Choles... [Published Bloomberg via Google News - Aug 31 2014]
Sanofi and Regeneron Announce Presentation of -2- [Published Scottrade - Aug 31 2014]
Early data suggest Sanofi, Regeneron drug may h... [Published Sharenet - Aug 31 2014]
Sanofi and Regeneron Announce Presentation of D... [Published PR Newswire - Aug 31 2014]
Sanofi and Regeneron Present Detailed Positive ... [Published Sanofi.com - Last press releases - Aug 31 2014]
Regeneron and Sanofi Announce Presentation of D... [Published PR Newswire: General Business - Aug 31 2014]
As battle over AstraZeneca looms, one lab in Sl... [Published Guardian.co.uk - Aug 31 2014]
Barry’s Appliance & TV hosts cooking extravaganza [Published Home News Tribune - Aug 30 2014]
JandJ And Bristol-Myers Changing The Myeloma Dr... [Published Bidness Etc - Aug 30 2014]
Guest column: A renaissance at Magazine Beach Park [Published Wicked Local Cambridge - Aug 30 2014]
NECTAR-HF Vagal-Nerve Stimulation Study Misses ... [Published Diabetes Care - Aug 30 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published MarketResearch.com - Aug 30 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Sanofi-Regeneron's Amgen Drug Rival Cuts Choles... [Published Bloomberg via Google News - Aug 31 2014]
Sanofi-Regeneron's Amgen Drug Rival Cuts Cholesterol Bloomberg ... to be number one,” Elias Zerhouni, Sanofi's head of research and development, said in a telephone interview. Sales of alirocumab may reach 1 billion euros ($1.3 billion) by 2020, ...
Regeneron and Sanofi Announce Presentation of D... [Published PR Newswire: General Business - Aug 31 2014]
TARRYTOWN, New York and PARIS, Aug. 31, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with ...
Global Adhesion Barriers Market 2014-2018: Key ... [Published PR Newswire: General Business - Aug 29 2014]
DUBLIN, August 29, 2014 /PRNewswire/ -- Dublin - Research and Markets (http://www.researchandmarkets.com/research/h73gdt/global_adhesion) has announced the addition of the "Global Adhesion Barriers Market 2014-2018" report to their... ...
Research and Markets: Global Adhesion Barriers ... [Published Business Wire Health News - Aug 29 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9892rc/global_adhesion) has announced the addition of the "Global Adhesion Barriers Market 2014-2018" report to their offering. An adhesion barrier or anti-adhesion ...
IBM’s artifical intelligence program Watson is ... [Published HDTV UK - Aug 29 2014]
It might not have the charm of Martin Freeman, but IBM’s cognitive computing program Watson could even out-think Sherlock Holmes. Three years ago, it beat US quiz show Jeopardy’s most successful contestant of all time, Ken Jennings. In future, it could ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Sanofi takes aim at dengue fever [Published Reuters Video: Top News - Jul 11 2014]
Sanofi takes aim at dengue fever [Published Reuters Video: Business - Jul 11 2014]
1

Press Releases

sort by: Date | Relevance
Sanofi and Regeneron Present Detailed Positive ... [Published Sanofi.com - Last press releases - Aug 31 2014]
The Zacks Analyst Blog Highlights: RadioShack, ... [Published Financial Services - Aug 28 2014]
Pharma Equities Technical Analysis -- Sanofi, A... [Published Financial Services - Aug 26 2014]
Sanofi and Regeneron to Present Results from Fo... [Published Sanofi.com - Last press releases - Aug 25 2014]
Epizyme, Panera, Amicus Therapeutics, Sanofi an... [Published Financial Services - Aug 22 2014]
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.